Dogan Koseoglu

Effect of Peroxisome Proliferator—Activated Receptor-γ Agonist Rosiglitazone on the Induction of Endometriosis in an Experimental Rat Model

Objective: To assess the effect of the peroxisome proliferator-activated receptor (PPAR)-γ agonist rosigliotazone on the induction of endometriosis in a rat model. Methods: Endometriosis was surgically induced in 28 rats by transplanting an autologous fragment of endometrial tissue onto the inner surface of the abdominal wall. Group I was assigned as control and no medication was administered. Starting 3 days before the operation and continuing for 4 weeks, 0.2 mg/kg/d rosiglitazone was administered to the study group orally. Four weeks later rats were killed and ectopic uterine tissues were evaluated morphologically and histologically. Scoring systems were used to evaluate preservation of epithelia. Results: Four rats in the study group and one rat in the control group died of complications related to surgery. There was a significant difference in post-treatment spherical volumes (64.00 mm3 [interquartile range (IQR): 354.42] vs 41.60 mm3 [IQR: 37.87], P = .018) and explant weights (77.97 mg [IQR: 431.27] vs 47.24 mg [IQR: 43.01], P = .005) between control and rosiglitazone-treated groups. The epithelia were found to be preserved significantly better in the control group when compared with the roziglitazone-treated group (2.00 [IQR:2.00] vs 0.00 [IQR:2.25], P = .014). Conclusions: Rosiglitazone was found to affect the induction of endometriosis negatively in this experimental rat model and seemed to interfere with the growth and maintenance of the uterine explant.

Peroxisome proliferator‐activated receptor‐gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model

Background:  The effect of rosiglitazone, an activator of peroxisome proliferator‐activated receptor‐gamma, on the growth of ectopic uterine tissue was assessed.

Scleredema treated with broad‐band ultraviolet A phototherapy plus colchicine

Scleredema is an uncommon condition characterized by induration of skin. The pathogenesis is not known, although the increased expression of collagen‐producing fibroblasts in the skin has been demonstrated. Scleredema has been difficult to treat with scattered reports of success with bath psoralen plus ultraviolet A (PUVA), cream PUVA, UVA1 and others. The use of low‐dose broad‐band UVA phototherapy was found to be effective in the treatment of morphea. Colchicine has been shown to interfere with collagen synthesis and is used successfully in scleroderma. We report the first case of scleredema that improved markedly with low‐dose broad‐band UVA plus colchicine treatment.

Angiolymphoid hyperplasia with eosinophilia mimicking Bowenoid papulosis

Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare, benign condition of unknown aetiology characterized by single or multiple brown-red nodules or plaques, usually occurring in the head and neck region, with a reported predilection for the retroauricular area. ALHE is considered to be a vascular proliferative disease, with marked proliferation of blood vessels lined by ‘‘hobnail’’ endothelial cells in conjunction with a dense inflammatory infiltrate mainly composed of eosinophils and lymphocytes. Involvement of the inguinal region is exceedingly rare, with only a few cases reported in the literature involving the penis, inguinal folds and vulvae. In this report, we describe an unusual case of ALHE, presenting with hyperpigmented brownish to pink plaques on the inguinal folds, scrotum and perineal area, masquerading as Bowenoid papulosis.

Morbilliform drug eruption due to pegylated α-interferon can show complete regression after switching to non-pegylated interferon.

Pegylated or non‐pegylated α‐interferon are frequently used medications for the treatment of both chronic hepatitis B and chronic hepatitis C. Skin disorders, which are mainly comprised of eczematous dermatitis, are frequently seen during treatment with this drug. However, drug eruption or morbilliform eruptions due to interferons have been rarely reported so far. We herein describe a patient who developed morbilliform drug eruption under treatment with pegylated interferon. She was able to continue treatment after switching from pegylated interferon to conventional interferon.

Hyperpigmented mycosis fungoides: a case report

982

Neutrophil-lymphocyte and platelet-lymphocyte ratios in endometrial hyperplasia

Objective The purpose of present study was to evaluate association between neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) and endometrial hyperplasia (EH). Methods One hundred and ten women with abnormal uterine bleeding were included into the study. Blood samples were drawn from all patients to obtain complete blood cell counts, neutrophil-leukocyte ratio and platelet-leukocyte ratio before endometrial curettage procedure initiated. The patients were divided into three groups due to their pathological results: group 1, patients with EH without atypia (n=40); group 2, patients with EH with atypia (n=15); and group 3, patients with neither hyperplasia nor cancer as control group (n=55). Blood cell counts, NLRs and PLRs were compared among these groups. Results Based on hemoglobin and platelet counts, there was no significant difference among these groups (P>0.05). Leukocyte and neutrophil counts were higher in group 2 (EH with atypia) than group 1 and group 3 (P<0.01). NLR of group 2 was significantly elevated when compared to group 1 and group 3 (P=0.004). PLR was higher in group 1 and group 2 than control group (P=0.024). Conclusion Non-specific inflammatory markers such as NLR and PLR were elevated in women with atypical EH. These markers may be used as a predictor of atypical EH in patients with abnormal uterine bleeding.

Coexistence of sacral dimple, solitary collagenoma and mid‐dorsal hypertrichosis in a child with occult spinal dysraphism

blood complement C1 inhibitor activity. Clin Chim Acta 1988; 174:121–30. 6 Drouet C, Blanch A, Roche O et al. Mutation analysis of the C1NH gene. J Allergy Clin Immunol 2004; 114:S66–74. 7 Cichon S, Martin L, Hennies HC et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79:1098–103. 8 Farsetti A, Misiti S, Citarella F et al. Molecular basis of estrogen regulation of the Hageman factor XII gene expression. Endocrinology 1995; 136:5076–83.

Mature cystic teratomas: Relationship between histopathological contents and clinical features

AIMS The aim of this study was to evaluate the relationship between pathological findings and clinical features in patients with ovarian mature cystic teratomas (MCTs). MATERIALS AND METHODS We reviewed and compared the demographic and clinical features of 32 patients confirmed pathologically as having MCT at a university hospital from 2009 to 2014, with MCT contents such as skin, hair, sebum, and cartilage. RESULTS The mean age of the patients was 33.7 ± 13.4 years. The mean tumor diameter was 7.1 ± 3.3 cm (range: 2-15 cm). The mean serum CA-19.9 level was 37.5 ± 79.5 IU/ml and the mean serum CA-125 level was 29.1 ± 33.0 IU/ml. The postmenopausal and pregnancy status rates of participants were 18.8, and 15.6%, respectively. The mean age, postmenopausal and pregnancy status, tumor size, symptoms related to MCT and laterality of the tumor did not differ among the patients according to the MCT contents. CONCLUSIONS Our findings suggest no relationship between the clinical features and histopathological contents of MCTs.

Coexistence of lichen aureus with familial Mediterranean fever

© 2007 The Authors 1001 JEADV 2007, 21, 977–1010 Journal compilation